Hepatic impairment No dose adjustment is necessary in clients with moderate or average (Boy or girl-Pugh A or B) hepatic impairment (see portion five.two). Publicity to midostaurin and its Energetic metabolite CGP62221 is considerably decreased in people with intense hepatic impairment than that in clients with standard hepatic operate (see part 5.